Archerfish Precision Diagnostics and C2N Diagnostics Announce Strategic Collaboration to Bring Advanced Alzheimer's Diagnostic Testing to Singapore and Across Asia
- archerfishdx
- Jul 24
- 4 min read
24 July 2025, Singapore
Archerfish Precision Diagnostics (Archerfish), a premier diagnostic laboratory serving Singapore and the broader Asian region and C2N Diagnostics, LLC (C2N), a leader in advanced brain health diagnostics, today announced a strategic partnership to introduce and expand access to C2N's innovative blood-based diagnostic test for Alzheimer's Disease (AD). This collaboration marks a significant step forward in improving early and accurate diagnosis of AD, a critical need across Asia.
The partnership will leverage Archerfish's extensive network and expertise in laboratory services and patient outreach throughout Singapore and other key Asian markets. This will facilitate the widespread availability of C2N's cutting-edge PrecivityAD2™ blood test, which offers a less invasive and more accessible method for detecting amyloid pathology in the brain, a hallmark of AD, all through a single blood draw.
Embracing breakthrough technology in Alzheimer’s Disease diagnostics
This innovative diagnostic test is the first of its kind in Singapore and signals a step towards more accessible, non-invasive AD diagnostics. The PrecivityAD2™ blood test is intended for individuals 55 and older who are being evaluated by a healthcare provider for AD or other causes of cognitive decline. Using high resolution liquid chromatography, tandem mass spectrometry, PrecivityAD2™ detects specific amyloid beta and tau peptides circulating in blood that are associated with the presence of amyloid plaques in the brain that can aid healthcare providers in the diagnosis of AD.
Early and accurate diagnosis of AD is paramount for several reasons: it allows patients and their families to plan for the future, access appropriate care and support services, and potentially enrol in clinical trials for emerging therapies. Traditional diagnostic methods can be invasive, costly, and often inaccessible in many regions. C2N's PrecivityAD2™ blood test aims to overcome these barriers, providing a more convenient and scalable solution.
Addressing Alzheimer’s Disease in Singapore’s Ageing Population
In light of a rapidly ageing population, this partnership seeks to strengthen local capabilities for AD diagnosis. Currently, approximately 1 in 11 adults aged 60 years and over suffer from dementia, including AD¹. By 2030, around 1 in 4 citizens (24.1%) will be aged 65 & above.² Given that the risk of dementia increases with age, Singapore will likely see a rise in the number of cases as her population continues to age, highlighting the need for accessible yet highly accurate diagnostic tools such as PrecivityAD2™.
While cognitive issues may have many potential causes, the PrecivityAD2™ blood test can provide greater clarity in an AD diagnosis. The PrecivityAD2™ test result is a clinically validated algorithm that can either confirm the presence of amyloid pathology and increase confidence in an AD diagnosis to enable patients to take timely action to manage their condition or rule out AD as a cause for cognitive decline, thus avoiding additional rounds of testing and accelerating a timely intervention. In either case, PrecivityAD2™ empowers healthcare providers and patients to improve healthcare outcomes through increased diagnostic certainty.
“We are delighted to partner with Archerfish to bring our advanced AD diagnostic solution to patients and clinicians in Singapore and across Asia,” said Joel Braunstein, CEO and President of C2N. “This collaboration aligns with our mission to transform brain health by providing innovative, accessible, and reliable diagnostic tools. Archerfish's deep understanding of the regional healthcare landscape and their commitment to excellence make them an ideal partner to help us address the growing burden of Alzheimer's disease in this part of the world.”
Dr Chris Tan, Group Chief Executive Officer, Archerfish Precision Diagnostics commented, “Archerfish is committed to bringing the most advanced and impactful diagnostic technologies to our patients. The partnership with C2N Diagnostics represents a pivotal moment in our efforts to combat AD in Asia. We believe that C2N’s PrecivityAD2™ will revolutionize how AD is diagnosed, enabling earlier intervention and better patient outcomes. We look forward to working closely with C2N to ensure broad access to this vital test.”
“Accurate and accessible diagnosis is an important cornerstone in the management of Alzheimer’s Disease. With advances in blood-based biomarkers, we are seeing new possibilities that complement standard diagnostic methods and support more timely clinical decision-making. Such developments hold promise for improving care for individuals experiencing cognitive decline,” said Professor Christopher Chen, Director, Memory Aging and Cognition Centre, National University Health System.
About Archerfish Precision Diagnostics
Archerfish Precision Diagnostics is a company focused on developing and launching novel diagnostic tests that address the unique healthcare requirements of the Asian community.
It leverages an expert team comprising leading scientists, healthcare administrators, and molecular pathologists to unify first-in-class diagnostics and introduce them to Singapore and the broader Asian market.
Formed through the merger of Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories, both CAP-accredited laboratories, Archerfish combines excellence in clinical laboratory practice with a strong commitment to research and development.
About C2N Diagnostics
C2N Diagnostics is a U.S-based specialty diagnostics company dedicated to advancing the field of brain health through cutting-edge diagnostic technology. Their innovative products and services enhance patient care and support clinical trials for neurodegeneration treatment. With strong foundations in scientific research and global clinical partnerships, C2N remains committed to transforming the way brain disorders are diagnosed, understood, and treated around the world.
Contact Information
Archerfish Precision Diagnostics
Angeline Wong
C2N Diagnostics
Joni Henderson
¹ Subramaniam M, Abdin E, Asharani PV, Roystonn K, Devi F, Peizhi W, et al. Prevalence of dementia in Singapore: Changes across a decade. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2025;21(2):10.1002/alz.14485. https://pubmed.ncbi.nlm.nih.gov/39868432/